An open-label, dose-escalation phase lb study of subcutaneous daratumumab with recombinant human hyaluronidase in patients with relapsed or refractory multiple myeloma (PAVO).

被引：1

作者：

Nahi, Hareth

Hellemans, Peter

Masterson, Tara J.

Clemens, Pamela L.

Ahmadi, Tahamtan

San Miguel, Jesus

Mateos, Maria-Victoria

Usmani, Saad Zafar

机构：

[1] Karolinska Univ Hosp, Karolinska Inst, Huddinge, Sweden

[2] Karolinska Univ Hosp, Dept Med, Huddinge, Sweden

[3] Janssen Res & Dev, Beerse, Belgium

[4] Janssen Res & Dev, Spring House, PA USA

[5] Univ Navarra Clin, Pamplona, Spain

[6] Univ Hosp Salamanca, IBSAL, Salamanca, Spain

[7] Levine Canc Inst, Carolinas Hlth Care Syst, Charlotte, NC USA

来源：

关键词：

D O I：

10.1200/JCO.2016.34.15_suppl.TPS8071

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

TPS8071

引用

页数：2